Affimed N.V. | CIK:0001608390 | 3

  • Filed: 3/20/2018
  • Entity registrant name: Affimed N.V. (CIK: 0001608390)
  • Generator: QXi
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1608390/000095010318003510/0000950103-18-003510-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1608390/000095010318003510/afmd-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001608390
  • Open this page in separate window: Click
  • ifrs-full:DisclosureOfRelatedPartyExplanatory

    (i)Shareholders

     

    As of December 31, 2017, no shareholder (December 31, 2016: one shareholder) holds more than 20% of the voting rights.

     

    (ii)Transactions with key management personnel

     

    The compensation of managing directors and other key management personnel comprised of the following:

     

       2015  2016  2017
              
    Short-term employee benefits   1,633    1,879    1,538 
    Termination benefits   0    430    0 
    Share-based payments   1,474    2,292    1,379 
        3,107    4,601    2,917 

      

    Remuneration of Affimed’s managing directors comprises fixed and variable components and share-based payment awards. In addition, the managing directors receive supplementary benefits such as fringe benefits and allowances. In the case of an early termination, the managing directors receive severance.

     

    Compensation for other key management personnel comprises fixed and variable components and share-based payment awards.

     

    The supervisory directors of Affimed N.V. received compensation for their services on the supervisory board of €375 (2016: €350; 2015: €296). In 2017, the Company recognized expenses for share-based payments for supervisory board members of €144 (2016: €381, 2015: €478).

     

    Selected managing directors and supervisory directors entered into service and consulting agreements with the Company:

     

    Dr. Ulrich Grau is a significant shareholder and Chairman of the Board of Directors of i-novion Inc., which was engaged by the Company to conduct preclinical services. In 2016, i-novion Inc. received related payments of €86.

     

    Jens-Peter Marschner rendered consulting services amounting to €11 in 2017 and €29 in 2016.

     

    The following table provides the total amounts of outstanding balances related to key management personnel:

     

        Outstanding balances 
        December 31, 2016    December 31, 2017 
               
    Thomas Hecht   23    19 
    Richard Stead   14    12 
    Berndt Modig   8    9 
    Ferdinand Verdonck   10    10 
    Ulrich Grau   17    17 
    Bernhard Ehmer   11    10 
    Jens-Peter Marschner   2    0